- Home
- VSTM vs TIL Comparison
VSTM vs TIL Comparison
Compare VSTM & TIL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VSTM
- TIL
- Stock Information
- Founded
- VSTM 2010
- TIL 2018
- Country
- VSTM United States
- TIL United States
- Employees
- VSTM N/A
- TIL N/A
- Industry
- VSTM Biotechnology: Pharmaceutical Preparations
- TIL Biotechnology: Pharmaceutical Preparations
- Sector
- VSTM Health Care
- TIL Health Care
- Exchange
- VSTM Nasdaq
- TIL Nasdaq
- Market Cap
- VSTM 425.9M
- TIL 230.1M
- IPO Year
- VSTM 2012
- TIL 2021
- Fundamental
- Price
- VSTM $4.68
- TIL $28.30
- Analyst Decision
- VSTM Strong Buy
- TIL Buy
- Analyst Count
- VSTM 9
- TIL 5
- Target Price
- VSTM $12.63
- TIL $119.00
- AVG Volume (30 Days)
- VSTM 2.5M
- TIL 349.6K
- Earning Date
- VSTM 08-07-2025
- TIL 08-12-2025
- Dividend Yield
- VSTM N/A
- TIL N/A
- EPS Growth
- VSTM N/A
- TIL N/A
- EPS
- VSTM N/A
- TIL N/A
- Revenue
- VSTM $10,000,000.00
- TIL N/A
- Revenue This Year
- VSTM $129.06
- TIL N/A
- Revenue Next Year
- VSTM $306.32
- TIL N/A
- P/E Ratio
- VSTM N/A
- TIL N/A
- Revenue Growth
- VSTM N/A
- TIL N/A
- 52 Week Low
- VSTM $2.10
- TIL $9.62
- 52 Week High
- VSTM $9.10
- TIL $92.00
- Technical
- Relative Strength Index (RSI)
- VSTM 40.17
- TIL 46.80
- Support Level
- VSTM $4.01
- TIL $20.60
- Resistance Level
- VSTM $5.06
- TIL $25.95
- Average True Range (ATR)
- VSTM 0.34
- TIL 3.47
- MACD
- VSTM 0.02
- TIL -1.29
- Stochastic Oscillator
- VSTM 44.81
- TIL 22.74
About VSTM Verastem Inc.
Verastem Inc is late-stage development biopharmaceutical company, committed to advancing new medicines for patients battling cancer. Its pipeline is focused on novel anticancer agents that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, particularly RAF/MEK inhibition and FAK inhibition.
About TIL Instil Bio Inc.
Instil Bio Inc is a clinical-stage biopharmaceutical company focused on developing a cell therapy pipeline of autologous tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer. It is also engaged in developing a novel class of genetically engineered TIL therapies using its Co-Stimulatory Antigen Receptor, or CoStAR, platform. Its pipeline includes ITIL-306 which expresses a CoStAR molecule designed to recognize, a tumor-associated antigen that is expressed on numerous solid tumors, including ovarian cancer, uterine cancer, NSCLC, and renal cancer.